{"commentary":{"count":12,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06479135\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"POIESIS","nct_id":"NCT06479135","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=poiesis-nct06479135. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"POIESIS","arms":[{"description":"Navtemadlin administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Navtemadlin placebo administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.","label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Myelofibrosis","Post-PV MF","Post-ET Myelofibrosis","Primary Myelofibrosis","MF"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Navtemadlin","type":"DRUG"},{"name":"Navtemadlin placebo","type":"DRUG"},{"name":"Ruxolitinib","type":"DRUG"}],"last_update":"2025-09-25","lead_sponsor":"Kartos Therapeutics, Inc.","official_title":"A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2","timeFrame":"24 weeks"},{"measure":"To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2","timeFrame":"24 weeks"}],"references":[],"start_date":{"date":"2024-06-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","url":"https://clinicaltrials.gov/study/NCT06479135"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/poiesis-nct06479135"}